Investor Presentaiton

ORION ODM-105 (tasipimidine) and ODM-212 Phase Ila ongoing with ODM-105 for insomnia Potent and selective alpha 2A adrenoceptor agonist • Orion has long experience and proven track record with alpha 2 agonists (for example dexemedetomidine) • In animal models ODM-105 has shown typical alpha 2A adrenoceptor agonist effects such as sedation, decreased arousal and relief in anxiety Insomnia often comorbidity of pain Potential benefits: low abuse potential and lack of daytime sleepiness Phase I ongoing with ODM-212 - TEAD inhibitor ODM-212 is an oral small molecule blocking TEAD activity Targeted indication(s): solid tumours with YAP/TEAD activation 14 Investor Presentation Orion Corporation

View entire presentation